

1 **Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of**
2 **a 4th dose in severely immunocompromised patients with cancer**

3
4 Astha Thakkar¹, Kith Pradhan², Benjamin Duva¹, Juan Manuel Carreño^{3,5}, Srabani Sahu¹, Victor
5 Thiruthuvanathan¹, Sean Campbell⁶, Sonia Gallego¹, Tushar D Bhagat¹, Johanna Rivera⁷,
6 Gaurav Choudhary¹, Raul Olea¹, Maite Sabalza⁸, Lauren C. Shapiro¹, Matthew Lee¹, Ryann
7 Quinn¹, Ioannis Mantzaris¹, Edward Chu¹, Britta Will¹, Liise-anne Pirofski⁷, Florian Krammer^{3,4,5},
8 Amit Verma^{1*}, Balazs Halmos^{1*}

- 9 1. Department of Oncology, Montefiore Einstein Cancer Center, Albert Einstein College of
10 Medicine
11 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine
12 3. Department of Microbiology, Icahn School of Medicine at Mount Sinai
13 4. Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine
14 at Mount Sinai
15 5. Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of
16 Medicine at Mount Sinai
17 6. Department of Pathology, Montefiore Medical Center
18 7. Division of Infectious Diseases, Department of Medicine, Albert Einstein College of
19 Medicine and Montefiore Medical Center
20 8. EUROIMMUN, US

21
22 * Correspondence to:

23
24 Dr. Balazs Halmos, bahalmos@montefiore.org

25 or

26 Dr. Amit Verma, amit.verma@einsteinmed.edu

27
28 Keywords: COVID-19, Vaccine, Booster, Cancer

29
30
31
32 **Abstract** (150 words)

33 Cancer patients show increased morbidity with COVID-19 and need effective immunization
34 strategies. We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in
35 57% of patients that were seronegative after primary vaccination. The immune response is
36 durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against
37 wild-type SARS-CoV2 and BA1.1.529 at 6 months of follow up. A subset of severely
38 immunocompromised hematologic malignancy patients were unable to mount adequate immune

39 response after the 3rd dose and were treated with a 4th dose in a prospective clinical trial which
40 led to adequate immune-boost in 67% of patients. Low baseline IgM levels and CD19 counts
41 were associated with inadequate seroconversion. Booster doses induced limited neutralization
42 activity against the Omicron variant. These results indicate that vaccine booster-induced
43 immunity is durable in cancer patients and additional doses can further stimulate immunity in a
44 subset of hematologic malignancy patients.

45 **Statement of significance**

46 We demonstrate that a 3rd dose of vaccine leads to seroconversion in 57% of negative patients
47 with durable immune responses at 6 months. A 4th dose of vaccine can seroconvert hematologic
48 malignancy patients with higher baseline IgM and CD19 levels.

49

50 **Introduction**

51 It is now well-established that coronavirus disease 2019 (COVID-19) in patients with cancer
52 carries a higher morbidity and mortality, especially in patients with hematologic malignancies[1-
53 5]. While overall case fatality has decreased over time, mostly related to the impact of broad
54 vaccinations and improved supportive/antimicrobial management, a higher case fatality rate was
55 noted amongst cancer patients even during the Omicron (B.1.1.529) wave [6-8] . Advanced age,
56 co-morbidities and performance status have emerged as key factors adversely impacting
57 outcomes amongst patients with a cancer diagnosis[9]. Effective vaccines have been developed
58 and authorized by the FDA to combat this pandemic[10, 11]. However, emerging data suggests
59 that despite these vaccines inducing high levels of immunity in the general population, patients
60 with hematologic malignancies have lower rates of seroconversion as defined by severe acute
61 respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibody (anti-S antibody) titers [12,
62 13]. Evidence has also suggested that specific therapies, such as anti-CD20 antibodies, BTK-
63 inhibitors and stem cell transplantation (SCT) have an association with lower rates of
64 seroconversion [14-16].

65

66 We previously published preliminary results of a study defining notable impacts of a 3rd booster
67 dose of vaccine, demonstrating a more than 50% seroconversion rate amongst patients
68 remaining seronegative after primary vaccinations[17]. Since then, we have completed our
69 entire primary cohort to assess initial responses with a broad array of immunological assays
70 along with now additional significant follow up allowing assessment of key aspects of waning
71 immunity. Importantly, we additionally conducted a trial assessing the efficacy of fourth dose
72 vaccinations amongst a highly immune suppressed group of patients with no or limited response
73 to a prior booster vaccine dose. Here we present results of both key cohorts including results of
74 serological, T cell and neutralization assays as well as correlations with other baseline clinical,
75 treatment and laboratory parameters.

76

77

78

79 **Methods**

80 **Patient recruitment and follow-up (ClinicalTrials.gov identifier NCT05016622) :**

81 3rd dose study

82 We recruited patients via an informed consent process. Patients were required to be >18 years
83 of age and have a cancer diagnosis either on active treatment or requiring active surveillance.
84 Patients were also required to have received 2 doses of the mRNA COVID-19 vaccine or 1 dose
85 of the adenoviral vaccine prior to enrollment. After drawing baseline labs that included spike
86 antibody, a sample for T-cell assay and a biobank sample, patients received booster mRNA
87 vaccine (initially BNT162b2 per protocol, which was later amended to allow for booster mRNA-
88 1273 vaccine after the Food and Drug Administration (FDA) authorized “booster” doses in fall of
89 2021). Patients who had received Ad26.CoV2.S vaccine received a booster BNT162b2 vaccine.
90 The patients then returned for follow-up 4 weeks and 4-6 months after their booster dose and
91 their labs were repeated (Supplementary Fig 1).

92 4th dose study

93 We have previously reported preliminary findings of a 56% seroconversion rate for patients with
94 cancer who did not have a detectable immune response after 2 doses[17]. For patients who did
95 not seroconvert after 3 doses or had low antibody response (<1000 AU/mL as determined by
96 our in-house assay, Abbott) we hypothesized whether a ‘mix and match’ strategy with 4th dose
97 of COVID-19 vaccine would induce seroconversion/improved boosting of the humoral antibody
98 responses. To study this, we designed a protocol wherein patients who had received 3 prior
99 doses of mRNA vaccines and had undetectable anti-S antibody or had an anti-S antibody level
100 of <1000 AU/mL measured at least 14 days after 3rd dose, would be randomized to an mRNA vs
101 adenoviral 4th vaccine dose. Responses would be then assessed at 4 weeks after the 4th dose
102 through measurement of anti-S antibody results. We also measured complete blood counts,
103 quantitative immunoglobulin levels (IgG, IgA and IgM), lymphocyte subsets, T-cell responses
104 and neutralization activity at baseline and 4 weeks for each of these patients. Following the
105 implementation of this protocol, the Centers for Disease Control (CDC) published a statement
106 that advised that the mRNA vaccines should be preferentially administered over the adenoviral
107 vaccines given concern over rare side effects such as thrombocytopenia and thrombosis
108 syndrome. Following this advisory, we amended our protocol to allow recruitment in a cohort
109 that would receive a 4th dose of the BNT162b2 vaccine to comply with CDC guidelines
110 (Supplementary Fig 1).

111 Anti-SARS-CoV2 Spike (anti-S) antibody assay

112 The AdviseDx SARS-CoV-2 IgG II assay was used for the assessment of anti-S IgG antibody.
113 AdviseDx is an automated, two-step chemiluminescent immunoassay performed on the Abbott
114 i1000SR instrument. The assay is designed to detect IgG antibodies directed against the
115 receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. The RBD
116 is a portion of the S1 subunit of the viral spike protein and has high affinity for the angiotensin
117 converting enzyme 2 (ACE2) receptor on the cellular membrane[18, 19] The procedure, in brief,
118 is as follows. Patient serum containing IgG antibodies directed against the RBD is bound to
119 microparticles coated with SARS-CoV-2 antigen. The mixture is then washed of unbound IgG
120 and anti-human IgG, acridinium-labeled, secondary antibody is added and incubated. Following
121 another wash, sodium hydroxide is added and the acridinium undergoes an oxidative reaction,
122 which releases light energy which is detected by the instrument and expressed as relative light
123 units (RLU). There is a direct relationship between the amount of anti-spike IgG antibody and
124 the RLU detected by the system optics. The RLU values are fit to a logistic curve which was
125 used to calibrate the instrument and expresses results as a concentration in AU/mL (arbitrary

126 units/milliliter). This assay recently has shown high sensitivity (100%) and positive percent
127 agreement with other platforms including a surrogate neutralization assay)[20] and also
128 demonstrated high specificity both in the post SARS-CoV-2 infection and post vaccination
129 settings. The cutoff value for this assay is 50 AU/mL with <50 AU/ml values reported as
130 negative and the maximum value is 50000 AU/mL.

131

132

133 **SARS-CoV-2 Interferon Gamma Release Assay**

134 The EUROIMMUN SARS-COV-2 Interferon Gamma Release Assay (Quan-T-Cell
135 SARS-CoV-2) was used for the assessment of patients' T-cell response to SARS-CoV-2
136 antigens through analysis of the production of interferon gamma by patient T-cells after
137 exposure to SARS- CoV-2 specific proteins. The assay does not differentiate between vaccine-
138 or infection-induced T-cell responses. The SARS-CoV-2 IGRA assay is performed in two steps
139 as per manufacturer instructions, and a brief protocol follows. First, patient samples from lithium
140 heparin vacutainers are aliquoted into three separate tubes each. These tubes contain either
141 nothing ('blank'), general T-cell activating proteins ('mitogen'), or components of the S1 domain
142 of SARS-CoV-2 ('SARS-CoV-2 activated'). These samples were incubated at 37 degrees for 24
143 hours before being centrifuged and the plasma separated and frozen at -80 degrees for later
144 analysis. Samples were then batched to be run as a full 96 well plate along with calibrators and
145 controls. Plasma samples were unfrozen and added to an ELISA plate, which was prepared
146 with monoclonal interferon-gamma binding antibodies, along with calibrators and controls. After
147 incubation at room temperature the plate was washed and biotin-labeled anti-interferon gamma
148 antibody was added to bind the patient interferon gamma bound to the plate. The plate was
149 again incubated before being washed of excess antibody and a streptavidin-bound horseradish
150 peroxidase (HRP) enzyme added, which binds strongly to the biotin-labeled antibodies present.
151 This was again incubated and then washed of excess enzyme before a solution of H₂O₂ and
152 TMB (3,3', 5,5;-tetramethylbenzidine, a peroxide-reactive chromogen) is added and allowed to
153 react in the dark for 20 minutes. The reaction is then stopped through the addition of sulfuric
154 acid and the results read at 450 nM with background subtraction at 650 nM. Results for controls
155 and samples were quantified by the calibration curve generated on the same plate, and results
156 were interpreted as long as controls were within the pre-specified range. Blank results for each
157 specimen set were subtracted from each tube in the set and the mIU/mL for both the mitogen
158 and SARS-CoV-2 activated samples were determined with the calibration curve. Samples with
159 mitogen results below 400 mIU/mL were considered 'invalid', as the overall T-cell activity for that
160 set was too low, and excluded from analysis. All other sample sets were interpreted as per
161 manufacturer's instructions based on the SARS-CoV-2 activated sample results: less than 100
162 mIU/mL were denoted as negative, and greater than or equal to 100 mIU/mL were denoted as
163 positive.

164

165 **Neutralization assays**

166 **Surrogate Virus Neutralization assay for wild type SARS-CoV-2**

167 The SARS-CoV-2 Surrogate Virus Neutralization Test Kit was used to measure antibodies that
168 inhibit the interaction between viral RBD and ACE2 receptor. This test kit uses purified human
169 ACE2 (hACE2) protein-coated enzyme-linked immunosorbent assay (ELISA) plates and
170 horseradish peroxidase (HRP)-conjugated RBD to monitor the presence of circulating

171 antibodies in samples, including peripheral/capillary blood, serum, and plasma, which block the
172 interaction of RBD-HRP with ACE2 with excellent correlation with the gold standard live virus
173 plaque reduction neutralization test.

174

175 The kit contains two key components: RBD-HRP and hACE2. The protein-protein interaction
176 between RBD-HRP and hACE2 is disrupted by neutralizing antibodies against SARS-CoV-2
177 RBD, if present in a sample. After mixing the sample dilutions with the RBD-HRP solution,
178 components are allowed to bind to the RBD. The neutralization antibody complexed to RBD-
179 HRP remains in the supernatant and is removed during washing, The yellow color of the
180 hACE2-coated wells is determined by the RBD HRP binding to the hACE2-coated wells after
181 incubation with 3,3',5,5'-tetramethylbenzidine (TMB), followed by a stop solution. After the
182 addition of the stop solution, a light-yellow color results from blocking agents interacting with
183 RBDs and inhibiting hACE2 interactions.

184 **Microneutralization assay (MNT).**

185 MNT assays were performed in a biosafety level 3 facility at the Icahn School of Medicine at
186 Mount Sinai (ISMMS) as previously described[21]. Briefly, Vero E6-TMPRSS2 cells were
187 seeded in 96-well cell culture plates at 20,000/well in complete Dulbecco's Modified Eagle
188 Medium (cDMEM). The following day, heat-inactivated serum samples were serially diluted (3-
189 fold) starting at a 1:10 dilution in 1x MEM (10x minimal essential medium (Gibco), 2mM L-
190 glutamine, 0.1% sodium bicarbonate (Gibco), 10mM 4-(2-hydroxyethyl)-1-
191 piperazineethanesulfonic acid (HEPES; Gibco), 100U/ml-1 penicillin, 100ug/ml-1
192 streptomycin (Gibco) and 0.2% bovine serum albumin (MP Biomedicals)) supplemented with
193 10% fetal bovine serum (FBS). The virus diluted at 10,000 tissue culture infectious dose 50%
194 (TCID₅₀) per ml of 1x MEM was added to the serum dilutions and incubated for 1h at room
195 temperature (RT). After removal of cDMEM from Vero E6 cells, 120µl/well of the virus - serum
196 mix were added to the cells and plates were incubated at 37°C for 1h. Mix was removed and
197 100µl/well of each corresponding serum dilutions were added in a mirror fashion to the cell
198 plates. Additional 100µl/well of 1x MEM 1% FBS (Corning) were added to the cells. Plates
199 were incubated for 48h at 37°C and fixed with a 10% paraformaldehyde solution (PFA,
200 Polysciences) for 24h at 4°C.

201 For staining, plates were washed with 200µl of PBS. Cells were permeabilized with
202 150µl/well PBS containing 0.1% Triton X-100 for 15min at RT. Plates were washed 3x with
203 PBST and blocked with 3% milk (American Bio) in PBST for 1h at RT. Blocking solution was
204 removed and 100µl/well of the biotinylated mAb 1C7C7 anti-SARS nucleoprotein antibody
205 (generated at the Center for Therapeutic Antibody Development at the ISMMS) were added at 2
206 µg/ml for 1h at RT. Plates were then washed 3x with PBST and the secondary antibody goat
207 anti-mouse IgG-HRP (Rockland Immunochemicals) was added at 1:3,000 in blocking solution
208 for 1h at RT. Plates were washed 3x with PBST, and SIGMAFAST OPD (o-phenylenediamine,
209 Sigma-Aldrich) was added for 10 min at RT. The reaction was stopped with 50µl/well 3M
210 hydrochloric acid to the mixture. Optical density (OD₄₉₀) was measured on an automated plater
211 reader (Sinergy 4, BioTek). The inhibitory dilution 50% were calculated as previously described
212 [22].

213 **Statistical analysis**

214 The primary endpoint of the third dose study was to assess the rate of booster induced
215 seroconversion amongst patients who remained seronegative at least 28 days following
216 standard set of FDA authorized COVID-19 vaccinations. We hypothesized that booster dosing
217 would convert at least 30% of the enrolled seronegative patients to seropositive as defined by
218 our institutional Clinical Laboratory Improvement Amendments (CLIA) certified SARS-CoV-2
219 spike IgG assay (as compared to 10% as our null hypothesis). In a pre-specified analysis, at
220 least 26 evaluable seronegative patients were required to have sufficient power to be able to
221 reach this assessment. A McNemar's test was used to determine the equality of marginal
222 frequencies for paired nominal data with the aid of a homogeneity of stratum effects (HSE) test
223 to check if the effect was the same across all levels of a stratifying variable[23]. A Wilcox test
224 was used to determine if titers of two paired observations have changed over time subsequently
225 using a Kruskal Wallis test to determine if this difference is associated with another variable. For
226 the 4th dose study, a responder was considered any patient who showed seroconversion from
227 negative anti-S antibody to positive anti-S antibody at 4 weeks after 4th dose or increase in titer
228 to >1000 AU/mL at 4 weeks after the 4th dose. An alpha < 0.05 was considered statistically
229 significant. Correlation between continuous variables was assessed using Spearman's test. All
230 analyses were performed in R (version 3.6.2). This study was approved by The Albert Einstein
231 College of Medicine Institutional Board Review.

232

233

234 Results

235 *Duration of immune responsiveness after third dose of covid vaccine in cancer patients:*

236 Baseline characteristics

237 We previously reported outcomes for 88 patients enrolled into this study[17]. Here we present
238 our final results for the complete cohort of 106 patients that were enrolled into this study for
239 assessment of the primary endpoint of response at 4 weeks as well as 47 patients who
240 completed 4-6 month follow-up. The baseline characteristics of this cohort are summarized in
241 **Table 1**. The median age was 68 years (63.25-76.5 years)). Fifty five percent (58/106) of
242 patients were female and 45% (48/106) were male. Our cohort was ethnically diverse and
243 included 34% (36/106) Caucasian, 31% (33/106) African-American, 25% (27/106) Hispanic and
244 8% (9/106) Asian patients. Majority of patients had received mRNA vaccines at baseline. Sixty-
245 eight percent (72/106) received BNT162b2, 26% (28/106) received mRNA-1273 and 6% (6/106)
246 had received Ad26.CoV2.S. Seventy four percent of patients (78/106) received a booster
247 BNT162b2 vaccine and 26% (28/106) patients received booster mRNA-1273 vaccine. The
248 majority of the patients, 62% (66/106), had a hematologic malignancy and 38% (40/106) had a
249 solid tumor diagnosis. Further breakdown of cancer type and cancer status is summarized in
250 **Table 1**. The majority of patients, 75% (80/106), were being actively treated at the time of
251 receiving their booster vaccine.

252 Serology results

253 Thirty three percent of the patients (35/106) were seronegative after 2 doses. At 4 weeks
254 following the receipt of the booster vaccine, 57% (20/35) of these patients seroconverted and
255 had a detectable antibody response as demonstrated by anti-S antibody testing, meeting the
256 primary endpoint of our study. The median titer at baseline for the entire cohort was 212.1
257 AU/mL (IQR 50-2873 AU/mL) and the median titer at 4 weeks for the entire cohort was 9997
258 AU/mL (IQR 880.7-47063 AU/mL) (**Fig 1A**). The median rise in anti-S titer for patients with
259 hematologic malignancies was 2167 AU/mL (IQR 0-10131 AU/mL) versus 31010 AU/mL (IQR
260 9531-44464 AU/mL) in patients with solid malignancies ($p<0.001$). Within the hematologic
261 malignancies, patients with lymphoid cancers had a lower rise in median anti-S titers (1169
262 AU/mL, IQR 0-8661 AU/mL) compared to those with myeloid malignancies; median anti-S titer
263 9424 AU/mL (IQR 4381-20444 AU/mL) ($p<0.001$) (**Fig 1B**).

264 We further investigated the association of specific anti-cancer therapies with the booster effect.
265 Patients on BTKi therapy ($n=12$) had a median rise in anti-S antibody of 0 AU/mL (IQR 0-3393
266 AU/mL) compared to a median rise of 9355 AU/mL (IQR 877.3-34410 AU/mL) in anti-S antibody
267 for patients not on BTKi ($p<0.05$) (**Fig 1C**). Patients on anti-CD20 antibody therapy ($n=25$) also
268 had a median rise in anti-S antibody level of 0 AU/mL (IQR 0-910.5 AU/mL) compared to a
269 median rise of 12735 AU/mL (IQR 2842-38863 AU/mL) in patients that did not receive anti-
270 CD20 antibody therapy ($p<0.05$). (**Fig 1D**). Nine patients had a history of SARS-CoV-2 infection
271 and in this cohort the rise in anti-S titers was higher (median 19350 AU/mL, IQR 9286-32151
272 AU/mL), compared to those who did not have prior SARS-CoV-2 infection with a median anti-S
273 titer rise, 6706 AU/mL (IQR 444.1-33831 AU/mL). (**Fig 1E**). We also observed that the rise in
274 anti-S titer at 4 weeks was higher for patients who received a mRNA-1273 booster compared to
275 BNT162b2 booster; median 31451 AU/mL vs 5534 AU/mL respectively (**Fig 1F**). This
276 observation was not however, statistically significant. These results are also summarized in
277 **Table 2**.

278 **T cell immune responses**

279 We also studied T-cell immune responses through a SARS-CoV-2 interferon gamma release
280 assay. At baseline, 88 patients had evaluable T-cell results and a positive T cell response
281 against SARS-CoV-2 was seen in 74% (65/88) patients. Of these, 21 patients were
282 seronegative for anti-S antibody at baseline. At 4 weeks, 89 patients had evaluable T-cell
283 results and a positive result was seen in 85% (76/89) percent patients. Of the 15 patients with
284 negative anti-S antibody at 4 weeks, 11 had a positive T-cell response. Fourteen patients who
285 had a negative T-cell assay response at baseline had a positive T-cell response at 4 weeks.
286 Anti-S titer showed a positive correlation with T-cell response at baseline and at 4 weeks for this
287 cohort ($p<0.001$) (**Fig 1G**). These results are summarized in **Table 2**.

288 **Neutralization assays**

289 *Neutralization assay against wild type virus*

290 We tested neutralization pre- and post-3rd dose in this cohort using the GenScript surrogate
291 virus neutralization assay. At baseline, biobanked samples from 103 patients were tested for
292 neutralizing antibodies. Of these, 35 patients were seronegative at baseline and 68 patients
293 were seropositive. Neutralizing antibodies were detected in 47 of 68 (69%) patients who were
294 seropositive at baseline. The correlation between seropositivity and presence of neutralizing
295 antibodies was statistically significant ($p<0.001$, Fisher's exact test).

296 At 4 weeks post 3rd dose, samples from 100 patients were available for testing. Eighty five of
297 these patients were seropositive at 4 weeks and 15 were seronegative. Neutralizing antibodies
298 were detected in 77 of 85 (91%) seropositive patients at 4 weeks. The correlation between
299 seropositivity and presence of neutralizing antibodies was also statistically significant at 4 weeks
300 ($p<0.001$, Fisher's exact test).

301 We also analyzed the correlation of anti-S titers at baseline and 4 weeks to the percentage of
302 virus neutralization, with 30% or more neutralization being consistent with positive result for
303 detection of neutralizing antibodies. We observed that at baseline and 4 weeks, anti-S titers
304 correlated with percentage of viral neutralization with higher titers correlating with higher
305 percentage of viral neutralization (Figure **1H** <0.001 by Spearman rank correlation). These
306 results are summarized in **Table 2**.

307 *Neutralization against Omicron BA.1*

308 Thirty-five patients were found be seronegative after the 3rd dose. Due to the emergence of the
309 Omicron BA.1 wave, we further assessed neutralization activity for the seronegative cohort
310 (N=35) against wild type (WT) SARS-CoV-2 and BA 1.1.529 (Omicron BA.1). At 4 weeks
311 neutralization was noted in 46% patients (16/35) for the WT virus while only 17% of patients had
312 detectable neutralization activity (6/35) for the Omicron variant. These results are summarized
313 in **Table 2**.

314 **Six-month follow-up post 3rd dose of vaccine**

315 Forty seven patients (44%) out of 106 completed 4-6 months follow-up for the third dose study.
316 All these patients were seropositive 4 weeks after the 3rd dose and strikingly, we observed that
317 all patients maintained a positive anti-S antibody at 4-6 months follow-up. Eleven of these 47
318 patients had solid malignancies and 36 had hematologic malignancies. Six patients had

319 received anti-Covid monoclonal antibody (moAb) therapy as per standard of care (4
320 tixagevimab-cilgavimab or Evusheld, 1 casirivimab/imdevimab or regen-co-v, and 1 sotrovimab
321 between the 4-week and 4-6 months follow-up. A striking increase in titers in this small cohort of
322 patients was noted to a median titer of 17481.2 AU/mL. Four patients had breakthrough SARS-
323 CoV-2 infections and 9 patients had received a 4th dose of COVID-19 vaccine outside of the
324 context of the study prior to the time of 4-6 month follow-up. The median decline in titer for 41
325 patients who did not receive anti-SARS-CoV-2 moAb treatment in the interim to confound
326 results was -922.2 AU/mL. When compared to the antibody levels 4 weeks after booster
327 vaccination, the median percentage decline in titers was 56.4%. However, despite the noted
328 decline not a single patient in this cohort seroreverted (**Fig 1I**), especially when compared to
329 decline post 2 vaccines. In our initial report of seroconversion post-3rd booster, we reported
330 waning of immunity in 99 patients post 2 vaccines. The median decline in the 99 patient cohort
331 was 72.1% with 2 patients losing detectable antibody response [17]

332

333 ***Efficacy of 4th dose vaccine for patients that were seronegative or low seropositive after***
334 ***3rd dose***

335 **Baseline characteristics**

336 Eighteen patients were enrolled into the 4th dose study. Median age for this cohort was 69.5
337 years (IQR 65.5-73.8). Thirty nine percent (7/18) were seronegative at baseline and 61%
338 patients (11/18) were sero-low (anti-S ab <1000 AU/mL). All patients had hematologic
339 malignancies in this cohort and the breakdown of diagnoses is provided in **Table 3**. Eighty three
340 percent of the patients (15/18) received BNT162b2 4th booster shots and 17% (3/18) patients
341 received Ad26.CoV2.S as their 4th booster vaccine. In addition, we also measured baseline
342 complete blood counts (CBC), lymphocyte subsets, immunoglobulin G, A and M (quantitative Ig)
343 levels at baseline and 4 weeks. (**Table 4**).

344 **Anti-spike IgG responses after the 4th dose**

345 A patient was classified as a responder if they 1) had positive anti-S antibody at 4 weeks if
346 seronegative at baseline or 2) if they achieved a titer of >1000 AU/mL at 4 weeks if they were
347 sero-low at baseline. As such, we observed a 67% response rate (12/18) in patients for the 4th
348 dose cohort. Two of 7 seronegative patients seroconverted to positive anti-S antibody at 4
349 weeks with a seroconversion rate of 29% in this cohort. All low seronegative patients (11/11)
350 responded with an IgG level > 1000 after the 4th dose (**Fig 2A**). For the whole cohort, the
351 median anti-S antibody at baseline was 131.1 AU/mL (<50-432.9 AU/mL) and at 4 weeks was
352 1700 AU/mL (IQR 64.3-18627 AU/mL). We further investigated association of baseline
353 laboratory values, such as CBC, lymphocyte subsets and quantitative Ig levels and observed
354 that patients in the responder group had higher baseline IgM (60.5 mg/dl) compared with the
355 non-responder group (median 17 mg/dl, p<0.001) (**Fig 2B**). Additionally, we also observed that
356 the median CD19+ cell count was significantly lower in the non-responder group versus the
357 responder group (1 vs 113, p=0.04). These results are summarized in **Table 5**.

358 **T Cell activity against SARS-CoV-2 after the 4th dose**

359 T-cell activity was assessed at baseline and at 4 weeks using the SARS-CoV-2 interferon
360 gamma release assay. At baseline, 14 patients had evaluable T-cell responses and a positive

361 response was noted in 79% patients (11/14). Of these, 3 patients had negative anti-S antibody
362 at baseline. At 4 weeks after the 4th dose, a positive T-cell response was seen in 17/18 (94%)
363 patients. These results are summarized in **Table 5**.

364 **Neutralization activity against SARS-CoV-2 after 4th dose**

365 We also assessed neutralization activity at baseline and at 4 weeks against WT and Omicron (B
366 1.1.529, BA.1). The results are summarized in **Table 5**. Overall, neutralization activity was seen
367 in 67% patient samples at baseline and in 72% patient samples at 4 weeks. Strikingly,
368 neutralization activity against Omicron was absent in all patient samples at baseline, however
369 became detectable in 33% (6/18) patients at 4 weeks after the 4th dose. The titer of anti-S
370 antibody correlated with neutralization activity at baseline and at 4 weeks against the WT virus
371 ($p < 0.001$) (**Fig 2C**). We also observed correlation between the titer of anti-S antibody with
372 neutralization activity at 4 weeks for the Omicron variant (**Fig 2D**).

373 **Exploratory analysis for immunoglobulin levels**

374 The observation for baseline IgM correlating with response to the 4th dose of the COVID-19
375 vaccine led us to perform an exploratory analysis to assess if IgG and IgA levels would also
376 correlate with the response. Given that our 4th dose cohort was small, we performed this
377 exploratory analysis by combining the baseline immunoglobulin levels for the baseline
378 seronegative cohort for the 3rd dose study (n=35) and baseline immunoglobulin levels for the 4th
379 dose study (n=18). In this exploratory analysis, we observed that the median levels for all
380 immunoglobulin subtypes were lower in patients who either did not seroconvert after the 3rd
381 dose or did not respond to the 4th dose (IgA 49 mg/dL vs 116.5 mg/dL, IgM 16.6 mg/dL vs 48.3
382 mg/dL, IgG 488 mg/dL vs 759.5 mg/dL with p values of 0.05, 0.002 and 0.006 respectively
383 (Kruskal Wallis test).

384 **Discussion**

385 Since the authorization of 3rd doses for patients with a weakened immune system, several
386 studies have shown enhanced immunogenicity for a third dose of COVID-19 vaccine in patients
387 with cancer. [17, 24, 25] In particular, patients with lymphoid malignancies have been
388 consistently shown to have reduced seroconversion after 2 doses of the COVID-19 vaccines[26-
389 29]. Studies looking at immunogenicity of a 3rd dose of COVID-19 vaccines have reported that a
390 subset of these patients can be induced to have an immune response with the 3rd dose of the
391 COVID-19 vaccines.[17, 30]

392 Correlation between anti-S antibody titers and neutralization activity in patients with cancer has
393 been demonstrated [31]. However, the emergence of the Omicron (B.1.1.529) variant which was
394 discovered in November 2021 and then spread quickly globally, the situation changed. Omicron,
395 with its extensive mutations in neutralizing epitopes, is able to at least partially evade *in vitro*
396 neutralizing antibodies induced by 3rd doses in patients with cancer[31, 32]. The potential utility
397 and timing of a 4th COVID-19 vaccine dose has been brought up especially for those who are at
398 risk for poor seroconversion after 3rd doses[33], with the Centers for Disease Control (CDC)
399 recommending 2 additional boosters following a 3-vaccine primary series[34]. These variants in
400 part overcome vaccine-induced immunity and are resistant to many of the available monoclonal
401 antibody products[31, 32, 35].

402

403 Our results demonstrate that a 3rd dose of COVID-19 vaccine boosts detectable anti-SARS-
404 CoV-2 immunity in the majority of cancer patients and can seroconvert a subset of them not
405 responding to prior vaccine doses. The 3rd COVID-19 vaccine also results in boosting of T-cell
406 responses and leads to a rise in neutralizing antibodies. Patients who have received anti-CD20
407 antibody therapy or BTK inhibitors remain at risk for lower seroconversion whereas those who
408 have been infected with COVID-19 in the past, have a very strong immune response likely due
409 to immunologic memory. Our results show that the higher the titer of the anti-S antibody, the
410 higher likelihood of neutralization in a surrogate neutralization assay adding to the evidence that
411 this may be a good strategy to prevent symptomatic SARS-CoV-2 infection as well as an
412 appropriate surrogate marker to guide research and clinical management [36]. Our study also
413 provides the reassuring finding that the large majority of patients with cancer retain detectable
414 humoral immunity at 6 months post 3rd dose of COVID-19 vaccination.

415
416 Reports of efficacy of 4th COVID-19 vaccine doses are emerging. A study from Israel
417 demonstrated enhanced Omicron neutralization after a 4th dose of COVID-19 mRNA vaccine in
418 healthy health-care workers[37]. However a study of 25 patients with solid organ transplant
419 recipients showed that the 4th dose was not effective in inducing Omicron neutralization[38].
420 Such a study has not been published yet for patients with cancer, making this an unmet need.
421 We designed a prospective cohort study of a 4th dose of the COVID-19 vaccine in patients with
422 cancer precisely to address this question. Our results suggest that in cohorts of highly immune
423 suppressed patients, baseline assessment of immunity based on prior treatment history and
424 immunological markers such as IgM levels and CD19+ cell levels may help predict the response
425 to COVID-19 booster vaccinations and support administration of additional vaccine doses even
426 in highly immune suppressed individuals. Notably, serum IgM levels were previously shown to
427 correlate with mRNA vaccine responses of solid organ transplant recipients[39]. In addition,
428 further testing to assess serological and cellular markers of the response may be helpful to
429 identify the patients at highest risk to prioritize these patients for preventive/prophylactic
430 strategies as well as enrichment markers for further experimental studies. Finally, the 4th
431 vaccine dose results in a significant increase in anti-spike antibodies in low seropositive patients
432 and seroconversion in a proportion of seronegative immunosuppressed patients with cancer.
433 Similar to previous reports, the booster doses do lead to enhanced neutralization activity against
434 the WT virus, but not the Omicron (BA.1) variant. Future efforts are needed to evaluate variant-
435 specific vaccines as well as additional protective measures, such as passive immunization
436 strategies, especially for this immunosuppressed patient population that may not benefit as
437 much as healthy controls from booster doses of existing vaccines.

438 439 References

- 440 1. Kuderer, N.M., et al., *Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort*
441 *study*. *Lancet*, 2020. **395**(10241): p. 1907-1918.
- 442 2. Lee, L.Y.W., et al., *COVID-19 prevalence and mortality in patients with cancer and the effect of*
443 *primary tumour subtype and patient demographics: a prospective cohort study*. *Lancet Oncol*,
444 2020. **21**(10): p. 1309-1316.
- 445 3. Mehta, V., et al., *Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital*
446 *System*. *Cancer Discov*, 2020. **10**(7): p. 935-941.

- 447 4. Khoury, E., et al., *Differences in Outcomes and Factors Associated With Mortality Among*
448 *Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A*
449 *Systematic Review and Meta-analysis.* JAMA Netw Open, 2022. **5**(5): p. e2210880.
- 450 5. Tang, L.V. and Y. Hu, *Poor clinical outcomes for patients with cancer during the COVID-19*
451 *pandemic.* Lancet Oncol, 2020. **21**(7): p. 862-864.
- 452 6. Lee, M., et al., *Impact of COVID-19 on case fatality rate of patients with cancer during the*
453 *Omicron wave.* Cancer Cell, 2022. **40**(4): p. 343-345.
- 454 7. Pinato, D.J., et al., *Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among*
455 *vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective,*
456 *multicentre, OnCovid registry study.* Lancet Oncol, 2022.
- 457 8. Bestvina, C.M., et al., *COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related*
458 *Delays during the Omicron Wave: A Brief Report from the TERA-VOLT Analysis.* JTO Clin Res Rep,
459 2022: p. 100335.
- 460 9. Grivas, P., et al., *Association of clinical factors and recent anticancer therapy with COVID-19*
461 *severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.* Ann
462 Oncol, 2021. **32**(6): p. 787-800.
- 463 10. Sadoff, J., et al., *Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.* N Engl
464 J Med, 2021. **384**(23): p. 2187-2201.
- 465 11. Polack, F.P., et al., *Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.* N Engl J Med,
466 2020. **383**(27): p. 2603-2615.
- 467 12. Thakkar, A., et al., *Seroconversion rates following COVID-19 vaccination among patients with*
468 *cancer.* Cancer Cell, 2021. **39**(8): p. 1081-1090.e2.
- 469 13. Addeo, A., et al., *Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with*
470 *cancer.* Cancer Cell, 2021. **39**(8): p. 1091-1098.e2.
- 471 14. Schönlein, M., et al., *Risk factors for poor humoral response to primary and booster SARS-CoV-2*
472 *vaccination in hematologic and oncological outpatients-COVIDOUT study.* Cancer Cell, 2022.
- 473 15. Guven, D.C., et al., *Impact of Therapy in Patients with Hematologic Malignancies on*
474 *Seroconversion Rates After SARS-CoV-2 Vaccination.* Oncologist, 2022. **27**(4): p. e357-e361.
- 475 16. Dahiya, S., et al., *Impaired immune response to COVID-19 vaccination in patients with B-cell*
476 *malignancies after CD19 CAR T-cell therapy.* Blood Adv, 2022. **6**(2): p. 686-689.
- 477 17. Shapiro, L.C., et al., *Efficacy of booster doses in augmenting waning immune responses to*
478 *COVID-19 vaccine in patients with cancer.* Cancer Cell, 2022. **40**(1): p. 3-5.
- 479 18. Pillay, T.S., *Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein.* J Clin
480 Pathol, 2020. **73**(7): p. 366-369.
- 481 19. Yang, J., et al., *Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.*
482 Nat Commun, 2020. **11**(1): p. 4541.
- 483 20. Bradley, B.T., et al., *Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2*
484 *Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of*
485 *Sterilizing Immunity.* J Clin Microbiol, 2021. **59**(9): p. e0098921.
- 486 21. Carreño, J.M., et al., *Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.*
487 Nature, 2022. **602**(7898): p. 682-688.
- 488 22. Amanat, F., et al., *An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug*
489 *Screening.* Curr Protoc Microbiol, 2020. **58**(1): p. e108.
- 490 23. Zhao, Y.D., et al., *Testing homogeneity of stratum effects in stratified paired binary data.* J
491 Biopharm Stat, 2014. **24**(3): p. 600-7.
- 492 24. Munro, A.P.S., et al., *Safety and immunogenicity of seven COVID-19 vaccines as a third dose*
493 *(booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a*

494 *blinded, multicentre, randomised, controlled, phase 2 trial*. *Lancet*, 2021. **398**(10318): p. 2258-
495 2276.

496 25. Shroff, R.T., et al., *Immune responses to two and three doses of the BNT162b2 mRNA vaccine in*
497 *adults with solid tumors*. *Nat Med*, 2021. **27**(11): p. 2002-2011.

498 26. Greenberger, L.M., et al., *Antibody response to SARS-CoV-2 vaccines in patients with*
499 *hematologic malignancies*. *Cancer Cell*, 2021. **39**(8): p. 1031-1033.

500 27. Perry, C., et al., *Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-*
501 *Hodgkin lymphoma*. *Blood Adv*, 2021. **5**(16): p. 3053-3061.

502 28. Herishanu, Y., et al., *Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic*
503 *lymphocytic leukemia*. *Blood*, 2021. **137**(23): p. 3165-3173.

504 29. Ghione, P., et al., *Impaired humoral responses to COVID-19 vaccination in patients with*
505 *lymphoma receiving B-cell-directed therapies*. *Blood*, 2021. **138**(9): p. 811-814.

506 30. Lim, S.H., et al., *Immune responses against SARS-CoV-2 variants after two and three doses of*
507 *vaccine in B-cell malignancies: UK PROSECO study*. *Nat Cancer*, 2022. **3**(5): p. 552-564.

508 31. Mack, P.C., et al., *Longitudinal COVID-19-vaccination-induced antibody responses and Omicron*
509 *neutralization in patients with lung cancer*. *Cancer Cell*, 2022.

510 32. Chang, A., et al., *Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA*
511 *Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia*. *J Clin*
512 *Oncol*, 2022: p. Jco2200088.

513 33. Ehmsen, S., et al., *Antibody responses following third mRNA COVID-19 vaccination in patients*
514 *with cancer and potential timing of a fourth vaccination*. *Cancer Cell*, 2022. **40**(4): p. 338-339.

515 34. [<COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised _](#)
516 [CDC.pdf>](#).

517 35. Zhou, H., et al., *SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic*
518 *Monoclonal Antibodies*. *bioRxiv*, 2022: p. 2022.02.15.480166.

519 36. Khoury, D.S., et al., *Neutralizing antibody levels are highly predictive of immune protection from*
520 *symptomatic SARS-CoV-2 infection*. *Nat Med*, 2021. **27**(7): p. 1205-1211.

521 37. Regev-Yochay, G., et al., *Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron*. *N*
522 *Engl J Med*, 2022. **386**(14): p. 1377-1380.

523 38. Karaba, A.H., et al., *A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the*
524 *Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response*.
525 *Transplantation*, 2022.

526 39. Azzi, Y., et al., *Risk factors associated with poor response to COVID-19 vaccination in kidney*
527 *transplant recipients*. *Kidney Int*, 2021. **100**(5): p. 1127-1128.

528

Table 1: Baseline characteristics for 3rd dose cohort.

Baseline characteristics	n=106
Age (median, IQR)	68 (63.25-76.5)
Sex	
Male	48(45%)
Female	58(55%)
Race	
Caucasian	36(34%)
African-American	33(31%)
Hispanic	27(25%)

Asian	9(8%)
Other	1(1%)
Previous vaccine given	
BNT162b2	72(68%)
mRNA-1273	28(26%)
Ad26.CoV2.S	6(6%)
Type of booster vaccine	
BNT162b2	78(74%)
mRNA-1273	28(26%)
Malignancy category	
Hematologic malignancy	66(62%)
Solid Malignancy	40(38%)
Lymphoid/Myeloid/Solid	
Lymphoid	55(52%)
Myeloid	11(10%)
Solid	40(38%)
Cancer status	
Active	69(65%)
Progressive	3(3%)
Recurrent	3(3%)
Relapse	7(7%)
Remission	24(23%)
On treatment at the time of booster	
Yes	80(75%)
No	26(25%)

529

Table 2. Results for 3rd dose of vaccine.				
Spike antibody results		n=106		
	4-week negative	4-week positive	Seroconversion rate	p value
Baseline negative	15	20	57%	<0.001*
Baseline positive	0	71		
Total	15	91		
Rise in spike antibody titers overall (AU/mL)	Median	IQR		
Titer at baseline	212.1	50-2873		
Titer at 4 weeks	9997	880.7-47063		
Rise in spike antibody titers (AU/mL)	Median	IQR		

Hematologic malignancy	2167	0-10131		<0.001 *
Solid malignancy	31010	9531-44464		
Rise in spike antibody titers by solid/lymphoid/myeloid (AU/mL)				
Lymphoid cancers	1169	0-8661		<0.001 *
Myeloid cancers	9424	4381-20444		
Solid cancers	31010	9531-44464		
Association with certain cancer-directed therapies				
Bruton's tyrosine kinase inhibitors				
Change in spike antibody titers (AU/mL)	Median	IQR		
Patients on BTKi (n=12)	0	0-3393		<0.001 *
Patients not on BTKi	9355	877.3-34410		
Anti-CD20 antibody treatment				
Change in spike antibody titers (AU/mL)	Median	IQR		
Patients on CD20 (n=25)	0	0-910.5		0.0133*
Patients not on CD20	12735	2842-38863		
Anti-CD20 antibody treatment within 6 months	Median	IQR		
Yes	0	0-0		0.0548 2
No	587	0-4314		
Change in spike antibody titer by prior COVID infection	Median	IQR		
Yes (n=9)	19350	9286-32151		0.3051
No (n=96)	6706	444.1-33831		
Change in spike antibody titer by type of booster given	Median	IQR		
BNT162b2	5534	433.8-18074		0.0901 4
mRNA-1273	31451	515.5-45057		
T-cell activity				
Baseline	n=88	%		
Positive	65	74%		
Negative	23	26%		
4-week	n=89			
Positive	76	85%		
Negative	13	15%		

Baseline Neutralization activity assay (all evaluable patients, WT virus)				
	Anti-S antibody negative	Anti-S antibody positive	Total	p value
Neutralizing antibodies detected	0	47	47	<0.001
Neutralizing antibodies not detected	35	21	56	
Total	35	68	103	
Four-week Neutralization activity assay (all evaluable patients, WT virus)				
	Anti-S antibody negative	Anti-S antibody positive	Total	p value
Neutralizing antibodies detected	0	77	77	<0.001
Neutralizing antibodies not detected	15	8	23	
Total	15	85	100	
Four week Neutralization assay (seronegative cohort 4 weeks)				
	n=35			
Wild type				
Negative	19	54%		
Positive	16	46%		
Omicron				
Negative	29	83%		
Positive	6	17%		

530

Table 3: Baseline characteristics of the 4th dose cohort.	
	N (%)
Baseline seronegative	7 (39%)
Baseline low positive (Spike ab <1000 AU/mL)	11 (61%)
Cancer diagnosis	
CLL	7 (39%)
Waldenstrom's Macroglobulinemia	3 (17%)
DLBCL	2 (11%)
Multiple Myeloma	2 (11%)
Mantle Cell Lymphoma	1 (6%)
Marginal Zone lymphoma	1 (6%)
Hodgkins lymphoma	1 (6%)
MDS	1 (6%)

Fourth dose vaccine type	
BNT162b2	15 (83%)
Ad26.CoV2.S	3 (17%)

531

Table 4: Correlation of 4th dose vaccine response with baseline characteristics.			
	Non-responder (n=6)	Responder (n=12)	p value
Age	79.5	67.5	0.01293 *
Baseline WBC	4.95	5.15	0.45
Baseline ANC	2.6	3.5	0.26
Baseline ALC	1.2	1.3	0.57
Baseline AMC	0.5	0.65	0.73
Baseline Absolute CD3	773	835.5	0.57
Baseline Absolute CD4	406.5	407.5	0.71
Baseline Absolute CD8	310	247	0.40
Baseline Absolute CD19	1	113.5	0.04874 *
Baseline Absolute CD16/56	243.5	200	0.57
Baseline IgG	777	757	0.51
Baseline IgA	90.5	118	0.57
Baseline IgM	17	60.5	0.001442 **
4 week WBC	5.1	5.8	0.40
4 week ANC	2.7	3.45	0.57
4 week ALC	1.1	1.4	0.60
4 week AMC	0.55	0.65	0.60
4 week absolute CD3	754	983	0.40
4 week absolute CD4	461.5	369.5	0.93
4 week absolute CD8	297.5	269	0.40
4 week absolute CD19	2.5	105	0.07
4 week absolute CD16/56	232.5	219	0.93
4 week IgG*	741.5	832	0.62
4 week IgA*	86	112	0.69
4 week IgM*	15	62	0.003561 **
*n=11 for responder group			

532

Table 5: Results for 4th dose study.			
Overall response	18		
Responder	12	67%	
Non-responder	6	33%	
Median age		IQR	
Responder	67.5	63.75- 70.75	0.01293 *
Non-responder	79.5	72.75- 81.75	
Median baseline IgM			

Responder	60.5		0.001442 * *
Non-responder	17		
Median spike antibody at baseline (AU/mL)	131.1	<50-432.9	
Median spike antibody at 4 weeks (AU/mL)	1700	64.3-18627	
T-cell activity at baseline	n=14		
Positive	11	79%	
Negative	3	21%	
T cell activity at 4 weeks	n=18		
Positive	17	94%	
Negative	1	6%	
Neutralization assay baseline	Negative	Positive	
WT	6(33%)	12(67%)	
Omicron	18(100%)	0(0%)	
Neutralization assay 4 week	Negative	Positive	
WT	5(28%)	13(72%)	
Omicron	12(67%)	6(33%)	

533

534 **Table legend:**

535 Table 1: Baseline characteristics of 3rd dose cohort

536 Table 2: Summary of results for 3rd dose cohort

537 Table 3: Baseline characteristics for 4th dose cohort

538 Table 4: Correlation of baseline characteristics with outcome for 4th dose cohort

539 Table 5: Summary of results for 4th dose cohort

540 **Figure legend**

541 Figure 1: Immunogenicity of 3rd dose of COVID-19 vaccine in seronegative cancer patients

542 Figure 1A: Figure showing change in anti-S antibody titer at 4 weeks for entire cohort

543 Figure 1B: Figure showing change in anti-S antibody titer at 4 weeks split by cancer type (solid
544 cancer, lymphoid cancer and myeloid cancer)

545 Figure 1C: Figure showing effect of Bruton's tyrosine kinase inhibitor (BTKi) therapy on anti-S
546 antibody titer at baseline and 4 weeks of 3rd dose

547 Figure 1D: Figure showing effect of anti-CD20 antibody therapy on anti-S antibody titer at
548 baseline and 4 weeks of 3rd dose

549 Figure 1E: Figure showing effect of prior COVID-19 infection on anti-S antibody titer at baseline
550 and 4 weeks of 3rd dose

551 Figure 1F: Figure showing effect of booster type (BNT162b2 vs mRNA 1273) on anti-S antibody
552 titer at baseline and 4 weeks of 3rd dose.

553 Figure 1G: Line diagram showing correlation between anti-Spike IgG titer and baseline T-cell
554 activity at baseline and 4 weeks

555 Figure 1H: Line diagram showing correlation between anti-S titer and signal inhibition for
556 neutralization against WT virus at baseline and 4 weeks.

557 Figure 1I: Anti-Spike IgG titres at baseline, 4 weeks and 6 months after 3rd dose of COVID-19
558 vaccine in cancer patients. Line shows means with error bars (S.D.).

559 Figure 2: Immunogenicity of the 4th dose of COVID-19 vaccine in cancer patients with
560 seronegativity after 3 doses

561 Figure 2A: Anti-spike IgG levels after the 4th dose of COVID-19 vaccine for the entire cohort

562 Figure 2B: Correlation of baseline IgM levels with response to 4th dose of vaccine

563 Figure 2C: Line diagram showing correlation between anti-S titer and neutralization activity for
564 WT virus at baseline and 4 weeks

565 Figure 2D: Line diagram showing correlation between titer and neutralization activity for
566 Omicron strain at baseline and 4 weeks

567

568 **Acknowledgements:** This study was supported with funding from the National Cancer Institute
569 Grant 3P30CA013330-49S3 and NCORP Grant 2UG1CA189859-06. The authors also
570 acknowledge support from the Jane and Myles Dempsey Family. The funders had no role in
571 study design, data collection and analysis, decision to publish, or preparation of the manuscript.
572 Work in the Krammer laboratory was partially funded by the Centers of Excellence for Influenza
573 Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of
574 Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014), by
575 the Collaborative Influenza Vaccine Innovation Centers (CIVICs contract # 75N93019C00051)
576 and by institutional funds. Finally, this effort was also supported by the Serological Sciences
577 Network (SeroNet) in part with Federal funds from the National Cancer Institute, National
578 Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003.
579 The content of this publication does not necessarily reflect the views or policies of the
580 Department of Health and Human Services, nor does mention of trade names, commercial
581 products or organizations imply endorsement by the U.S. Government.

582

583 **Author contributions:** Conception and design: AT, LCS, LAP, BH, AV. Patient referral
584 recruitment and follow-up: AT, LCS, BD, IM. Data curation: AT, LCS. Laboratory investigations:

585 JMCQ, SS, VT, SC, TDB, JR, RO, MS. Logistical support : ML, RQ. Administrative support: EC,
586 BW, FK, Data analysis: KP, All authors contributed to the writing of the manuscript.

587 **Conflict of interest statement:** The Icahn School of Medicine at Mount Sinai has filed patent
588 applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines
589 which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to
590 market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer
591 (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex.
592 The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.

Figure 1




Figure 1: Immunogenicity of 3rd dose of COVID-19 vaccine in seronegative cancer patients

Figure 1A: Figure showing change in anti-S antibody titer at 4 weeks for entire cohort

Figure 1B: Figure showing change in anti-S antibody titer at 4 weeks split by cancer type (solid cancer, lymphoid cancer and myeloid cancer)

Figure 1C: Figure showing effect of Bruton's tyrosine kinase inhibitor (BTKi) therapy on anti-S antibody titer at baseline and 4 weeks of 3rd dose

Figure 1D: Figure showing effect of anti-CD20 antibody therapy on anti-S antibody titer at baseline and 4 weeks of 3rd dose



Figure 1E: Figure showing effect of prior COVID-19 infection on anti-S antibody titer at baseline and 4 weeks of 3rd dose

Figure 1F: Figure showing effect of booster type (BNT162b2 vs mRNA 1273) on anti-S antibody titer at baseline and 4 weeks of 3rd dose.


Figure 1G: Line diagram showing correlation between anti-Spike IgG titer and baseline T-cell activity at baseline and 4 weeks

Figure 1H: Line diagram showing correlation between anti-S titer and signal inhibition for neutralization against WT virus at baseline and 4 weeks.

Figure 1I: Anti-Spike IgG titres at baseline, 4 weeks and 6 months after 3rd dose of COVID-19 vaccine in cancer patients. Line shows means with error bars (S.D.).



C



D




Figure 2: Immunogenicity of the 4th dose of COVID-19 vaccine in cancer patients with seronegativity after 3 doses

Figure 2A: Anti-spike IgG levels after the 4th dose of COVID-19 vaccine for the entire cohort

Figure 2B: Correlation of baseline IgM levels with response to 4th dose of vaccine

Figure 2C: Line diagram showing correlation between anti-S titer and neutralization activity for WT virus at baseline and 4 weeks

Figure 2D: Line diagram showing correlation between titer and neutralization activity for Omicron strain at baseline and 4 weeks